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Abstract
Background and Aims: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) 
therapies. The aims of this study were to describe the clinical features of this complication and 
identify clinically useful genetic markers so that these drugs can be avoided or so that monitoring 
can be intensified in high-risk patients.
Methods: Inflammatory bowel disease patients were recruited from 89 sites around the world. Inclusion 
criteria included normal renal function prior to commencing 5-ASA, ≥50% rise in creatinine any time after 
starting 5-ASA, and physician opinion implicating 5-ASA strong enough to justify drug withdrawal. 
An adjudication panel identified definite and probable cases from structured case report forms. 
A genome-wide association study was then undertaken with these cases and 4109 disease controls.
Results: After adjudication, 151 cases of 5-ASA-induced nephrotoxicity were identified. Sixty-
eight percent of cases were males, with nephrotoxicity occurring at a median age of 39.4 years 
(range 6–79 years). The median time for development of renal injury after commencing 5-ASA 
was 3.0 years (95% confidence interval [CI] 2.3–3.7). Only 30% of cases recovered completely after 
drug withdrawal, with 15 patients requiring permanent renal replacement therapy. A genome-wide 
association study identified a suggestive association in the HLA region (p = 1 × 10–7) with 5-ASA-
induced nephrotoxicity. A sub-group analysis of patients who had a renal biopsy demonstrating 
interstitial nephritis (n = 55) significantly strengthened this association (p = 4 × 10–9, odds ratio 3.1).
Conclusions: This is the largest and most detailed study of 5-ASA-induced nephrotoxicity to date. It 
highlights the morbidity associated with this condition and identifies for the first time a significant 
genetic predisposition to drug-induced renal injury.
Key Words: 5-Aminosalicylates; nephrotoxicity; renal failure pharmacogenetics; stratified medicine; ulcerative colitis
1. Introduction
5-Aminosalicylate (5-ASA) medications are the most frequently pre-
scribed class of drug to induce and maintain remission in patients 
with mild to moderately active ulcerative colitis.1 Originally admin-
istered in combination with sulfapyridine as sulfasalazine, 5-ASA is 
now more often coated with a resin/gel or as a pro-drug/dimer to 
enhance distal bowel delivery through preparations such as mesala-
zine, olsalazine and balsalazide.2 The use of these agents in main-
tenance therapy over decades means that long-term toxicity is an 
important consideration.
Nephrotoxicity associated with 5-ASA agents was first described 
in animal models and case reports in the 1970s and has since been 
reported multiple times for both sulfasalazine and the more modern 
5-ASA agents.3–8 In 1990 the UK Committee on Safety of Medicines 
issued an alert on nephrotoxic reactions to mesalazine.9 Data from 
clinical trials suggest an annual risk of 0.26% and data from a 
questionnaire sent to gastroenterologists estimated an incidence 
of 1 case per 4000 patient years.10,11 A  review of the UK General 
Practice Research Database calculated the incidence at 0.17 cases 
per 100 patients per year but the authors noted that only 13% of 
these patients had a histological diagnosis of interstitial nephritis.12 
Regular monitoring of renal function for the duration of therapy is 
recommended, although the cost–effectiveness of this approach has 
not been demonstrated.
Rare idiosyncratic drug reactions are often notoriously difficult to 
characterize due to the small number of cases available to individual 
researchers. The International Serious Adverse Events Consortium 
was launched in 2007 to facilitate the collection of large cohorts 
of patients who developed these rare serious drug side effects.13 
Members of this consortium have recently demonstrated the utility 
of using small numbers of well-characterized cases to identify strong, 
clinically useful genetic risk factors for serious adverse drug reac-
tions through genome-wide association study methodologies. Good 
examples of this approach are the identification of HLA-B*57:01 
as a major determinant of cholestatic liver injury associated with 
flucloxacillin and our recent identification of an association between 
HLA-DRB1*07:01 and thiopurine-induced pancreatitis.14,15
In this study we describe in detail, for the first time, a cohort of 
patients with inflammatory bowel disease (IBD) who developed 
nephrotoxicity subsequent to 5-ASA administration. We use this 
cohort to characterize the clinical features of this serious adverse event 
and then perform the first genome-wide association study to identify 
genetic risk factors for the development of drug-induced renal injury.
2. Methods
2.1. Patient recruitment
Individual study sites identified and recruited patients with 5-ASA-
induced nephrotoxicity. This study was open to recruitment at 118 
UK research sites (73.8% of the 160 acute NHS trusts in the UK) 
as well as 45 international sites. In total 77 sites from the UK and 
12 sites from outside the UK recruited one or more patients. The 
protocol was approved by the National Research Ethics Committee 
South West, Exeter, UK (10/H0203/76) and by all local research and 
development offices.
Inclusion criteria for patient recruitment required the presence of 
all of the following:
•	 Patient administered any 5-ASA compound for treatment of 
inflammatory bowel disease (Crohn’s disease, ulcerative colitis 
or IBD unclassified).
•	 Patient aged 6 or over.
•	 Normal creatinine or estimated glomerular filtration rate (eGFR) 
prior to first administration of 5-ASA or a creatinine that 
returned to the normal range after cessation of therapy.
•	 Rise in serum creatinine ≥50% any time after introduction of 
5-ASA.
•	 Physician opinion implicating 5-ASA strong enough to justify 
drug withdrawal, even if temporary.
Cases were identified from recruiting sites through clinics and sys-
tematic searches of historical records and pathology databases. 
Gastroenterologists who replied to a 2001–2002 UK survey of 
5-ASA-induced nephrotoxicity were encouraged to submit cases.10 
We invited clinicians who had submitted adverse drug reaction 
reports to the Medicines and Healthcare Products Regulatory 
Agency (MHRA) to consider recruiting patients. We also undertook 
direct advertising to patients through the national patient newsletter. 
Cases were recruited who developed nephrotoxicity between 1988 
and 2013 (73% of cases were diagnosed with renal injury after the 
year 2000).
2.2. Case adjudication
An anonymized case report form detailing demographic, clinical and 
drug history was completed with the aid of hospital records. Two 
6-mL EDTA blood samples were taken at this visit for DNA extrac-
tion (BD Vacutainer, USA). The case report forms also requested cre-
atinine levels and their corresponding dates at four time points: (1) 
at baseline (usually before 5-ASA commenced, but not exclusively); 
(2) at the recording of the first abnormal creatinine value; (3) the 
worst creatinine value; and (4) the best recovered creatinine value. 
After data collection, the last normal creatinine value before devel-
opment of renal injury was also obtained, if it was available (92/151 
cases), to enable better characterization of the time period. If a renal 
biopsy was performed, the anonymized report was requested.
To assess patient eligibility for entry to this study, at least three 
gastroenterologists and at least one nephrologist reviewed each case 
for causality at a dedicated in-person adjudication panel meeting. 
For each case the evidence implicating 5-ASA as the cause of nephro-
toxicity was assessed using an adapted version of the validated 
Liverpool Adverse Drug Reaction Causality Assessment Tool, dis-
played in Supplementary Figure 1.16 Patients were classified as defi-
nite, probable, possible or unlikely cases of 5-ASA nephrotoxicity 
based on the adjudicator’s independent assessment that the nephro-
toxicity was due to 5-ASA treatment. The panel discussed all cases 
before a final adjudication decision was reached. Only individuals 
classified as probable or definite cases of 5-ASA-induced nephrotox-
icity were taken forward for clinical and genetic analyses.
Concomitant administration of any medications known to 
cause nephrotoxicity classified the patient as a possible case and 
these cases were excluded. This included the use of (1) antibiot-
ics (penicillins, cephalosporins, ciprofloxacin, sulphonamides, 
rifampicin); (2) diuretics (furosemide, bumetanide, thiazides); (3) 
non-steroidal anti-inflammatory drugs; (4) proton pump inhibi-
tors; (5) allopurinol; (6) cimetidine; and (7) indinivir. The presence 
of uncontrolled diabetes, uncontrolled hypertension or peripheral 
vascular disease also classified the patient as a possible case of 
5-ASA-induced nephrotoxicity and such patients were not taken 
forward for analysis. A patient treated with 5-ASA for microscopic 
colitis was recruited in error but was excluded during the adjudica-
tion process.
Definite cases required the development of renal injury upon 
rechallenge with 5-ASA. Cases classified as probable demonstrated 
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a temporal relationship with 5-ASA administration with no other 
identifiable risk factors for renal injury as described above.
2.3. DNA extraction and genotyping
DNA was extracted from EDTA-stabilized blood using the Qiagen 
Autopure LS with Puregene chemistry. Samples were genotyped on 
the Illumina Infinium HumanCoreExome beadchip (Illumina, USA), 
which contains 264 909 haplotype-tagging single-nucleotide poly-
morphism (SNP) markers, and 244 593 exome-focused markers by 
the Broad Institute (Boston, USA).
2.4. Clinical data analysis
Paper case-report forms were entered into the electronic database 
before independent, two-person, unblinded data cleaning was under-
taken to ensure data quality prior to analysis. All data were analysed in 
R 3.0.2.17 Listwise deletion was used for missing data. Normality was 
tested for by the Shapiro–Wilks normality test (p < 0.05 considered 
non-parametric). Non-parametric data are presented with the median 
value and the 95% confidence interval (CI) of the median, with com-
parisons performed by a Wilcoxon signed rank test or χ2 test as appro-
priate. Logistic and multivariate regression was conducted in R with 
pre-set variables (no stepwise regression). The definition of a return to 
baseline creatinine was a return to the upper limit of the local hospital 
laboratory’s normal range or 120 µmol/L if this range was not known.
2.5. Genome-wide and HLA imputation and 
association analyses
Three samples failed DNA extraction and were unavailable for genetic 
analysis. Genotyping was performed on the remaining 148 cases adju-
dicated as definite or probable 5-ASA-induced nephrotoxicity using 
the HumanCoreExome SNP Chip. Genotypes were called using 
Gencall.18 We excluded SNPs with an Hardy-Weinberg Equilibrium 
[HWE] p < 0.0001 and a genotype success rate <0.99. We excluded 
indels. Exclusion criteria for case samples were a genotyping suc-
cess rate <0.98 and a heterozygosity rate > 4 SDs (no samples were 
removed based on these criteria). To improve calling of low-frequency 
variants we used zCall.19 After running zCall, SNPs were excluded if 
they had a HWE p < 0.0001, Minor Allele Frequency [MAF] <0.01 
or if they were duplicated. This left 264 088 autosomal SNPs for 
imputation. The control patients with Crohn’s disease and ulcera-
tive colitis were obtained from the UK IBD Genetics Consortium as 
part of the Wellcome Trust Case Control Consortium (WTCCC 1 for 
Crohn’s disease and WTCCC 2 for ulcerative colitis).20,21 There were 
1748 Crohn’s disease control samples genotyped on the Affymetrix 
500K SNP chip and 2361 ulcerative colitis samples genotyped on the 
Affymetrix 6 SNP chip available for this analysis. Preliminary qual-
ity control (QC) had already been performed on the 1748 Crohn’s 
disease and 2361 ulcerative colitis samples.20,21 From these two con-
trol cohorts, we excluded SNPs with a genotyping success rate <0.99, 
MAF <0.01 and a HWE p < 0.0001. This left 396 255 (Crohn’s dis-
ease) and 727 195 (ulcerative colitis) autosomal SNPs. To exclude 
ethnic outliers we performed principal components analysis using 
genome-wide complex trait analysis (GCTA).22 To generate the princi-
pal components we used a set of 36 702 SNPs that were imputed with 
R2 > 0.99 in the cases (see below) and directly genotyped in the two 
control cohorts and were not in strong linkage (r2 < 0.2).
Four 5-ASA nephrotoxicity cases and 62 control samples were 
excluded for being >4 SDs from the first or second principal compo-
nents. We used Kinship-based INference for Gwas [KING]23to test 
for cryptic relatedness between samples. If a case and control pair 
of samples had a kinship coefficient >0.2 we excluded the control 
sample, otherwise we excluded one of the pair of samples at random. 
One case sample and 13 control samples were excluded because of 
relatedness to other case or control samples. After exclusions this 
left 143 ‘probable’ and ‘definite’ cases. The ratio of Crohn’s disease 
to ulcerative colitis patients in the control group (59%) was similar 
to that in the case cohort (60%).
As previously,15 we used minimac24 to impute into the European 
phase 1 version 3 (20101123) SNP and indel reference panel to 
prevent spurious associations due to variations in genotyping chips 
between cohorts. Seventy-six percent of the 9 412 474 SNPs with 
MAF >1% frequency were imputed at R2 >0.6 in the cases, 75% in 
the Crohn’s disease controls and 82% in the ulcerative colitis con-
trols. As a different SNP genotyping chip was used for each of the 
three case and control cohorts, we focused subsequent association 
analyses on a very conservative subset of 2 883 071 SNPs that had 
an imputation R2 >0.95 in all three cohorts. For dedicated imputa-
tion of the HLA region we used SNP2HLA25 and imputed into the 
T1DGC reference panel of 5224 individuals that have had classical 
HLA alleles typed as well as SNPs and indels by the immunochip. 
Of the 8961 variants in the T1DGC panel, 8398 were captured with 
an INFO score >0.8. Mach2dat26 was used to perform association 
analyses for the genome-wide analyses and PLINK27 was used to 
perform association analyses for the HLA imputed analyses.
2.5. Data access
Phenotype and genotype data for cases are freely available upon 
request from the iSAEC Data Access Committee for users who 
comply with the Consortium’s Data Release and IP Policy.13 Data 
will be available from https://dataportal.saeconsortium.org/ within 
12 months of genotype completion. Raw genotype data are freely 
available to researchers upon request. For further data access details 
please contact: saec@c2b2.columbia.edu.
Genotype data for the WTCCC ulcerative colitis and Crohn’s 
disease cases are available from the European Genome-Phenome 
Archive at https://www.ebi.ac.uk/ega/home.
3. Results
3.1. Patient identification and adjudication
Through our international network of research sites we recruited 
a total of 204 IBD patients with suspected 5-ASA-induced nephro-
toxicity. All cases underwent a rigorous assessment of causality 
by an adjudication panel composed of nephrologists and gastro-
enterologists using a validated tool.16 After this panel meeting the 
development of nephrotoxicity could be confidently assigned to the 
administration of 5-ASA medications for 151 out of 204 patients. Of 
these 151 cases, 5 were classified as definite cases of 5-ASA-induced 
nephrotoxicity, as they had a second episode of kidney injury when 
re-challenged with the agent. The remaining 146 cases were classi-
fied as probable cases.
3.2. Clinical features of 5-ASA-induced 
nephrotoxicity
The 151 patients who were adjudicated as definite or probable cases 
comprised 58 patients with Crohn’s disease, 88 patients with ulcera-
tive colitis and 5 patients with IBD unclassified. Sixty-eight percent 
of cases recruited were male. The median age at diagnosis of Crohn’s 
disease was 29.5 years (95% CI 25.2–33.9) while the median age 
for ulcerative colitis was 29.7 years (26.7–32.8). One hundred and 
forty-six patients (97%) self-identified as being of white ethnicity, 
2 patients did not provide a reply while 3 patients reported mixed 
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ancestry. A  summary of the disease activity and location in the 
2 years prior to development of renal disease is show in Table 1.
The median duration of 5-ASA treatment prior to first detection 
of a raised creatinine was 3.0 years (95% CI 2.3–3.7). An abnormal 
creatinine was reported in 13% of cases within the first 12 months of 
treatment. For 27% of patients we were unable to find a creatinine 
between the initiation of the drug and the first abnormal creatinine 
measurement. In these patients the median time from starting the 
drug to detection of nephrotoxicity was 4 years (95% CI 2.73–5.28) 
while the cohort with interval measurements had a median time of 
2.5 years (95% CI 1.70–3.36, p = 6 × 10−4). There was no significant 
difference in creatinine level at detection of abnormal renal function 
(p = 0.75) or in the rate of recovery (p = 0.72) between these two 
groups.
The majority of patients (91%) received oral 5-ASA alone with 
an average daily dose of 2.3 g (95% CI 2.1–2.5). Twelve patients 
received a mix of oral and rectal 5-ASA, while 1 patient received only 
rectal 5-ASA preparations. The majority of patients were treated 
with mesalazine (Supplementary Table 1); however, most available 
5-ASA preparations are represented in the data. Figure  1 demon-
strates the median creatinine levels and the time period at which 
these levels were collected at each time point for all 151 patients 
who developed nephrotoxicity. The density estimates for this plot are 
shown in Supplementary Figures 2 and 3.
Forty-five patients (30%) demonstrated full recovery of renal 
function within the follow-up period (median follow-up period 
5.10 years, 95% CI 4.17–6.02). We undertook a multivariate regres-
sion analysis to investigate whether any clinical features were predic-
tive of renal function recovery after 5-ASA cessation (Supplementary 
Table 2). This analysis suggested that the length of 5-ASA treatment 
(p = 0.05) and the average dose of 5-ASA (p = 0.03) inversely cor-
related with the likelihood of renal function recovery, suggesting 
cumulative toxicity. It has been suggested that patients who develop 
nephrotoxicity and stop the agent within 10 months of starting are 
more likely to recover to a normal creatinine.28 We were unable to 
replicate this association in our data (p  = 0.53); however, patients 
who did recover renal function appeared to have been taking 5-ASA 
for a shorter period of time before developing nephrotoxicity (median 
794 days, 95% CI 459.13–1128.87 vs median 1461 days, 95% CI 
1008.80–1597.20, p = 0.02; Figure 2). Forty-three percent of patients 
were treated with steroids, which was not associated with a shorter 
time to recovery (p = 0.20) or an increased rate of recovery (p = 0.10).
Fifteen out of 151 patients (9.9%) received renal replacement 
therapy, which for 13 patients took the form of a renal transplant. 
The remaining two patients were dialysis-dependent at the date 
of study end. A  multivariate regression analysis identified peak 
creatinine (p = 0.008), treatment with steroids (p = 0.037) and pres-
ence of a renal biopsy (p = 0.045) as predictive of the need for renal 
replacement therapy (Supplementary Table 3).
In total 76 patients adjudicated as definite or probable underwent 
a renal biopsy, 57 of which demonstrated clear evidence of intersti-
tial nephritis. Of these, 58% demonstrated only chronic inflamma-
tory changes in the interstitium, with 22 and 20% demonstrating 
acute or acute on chronic interstitial inflammation respectively. The 
remaining 19 biopsies demonstrated evidence of glomerulosclerosis 
or were non-diagnostic.
3.3. Genetic determinants of 5-ASA-induced 
nephrotoxicity
The idiosyncratic nature of 5-ASA-induced nephrotoxicity suggests 
that there may be a genetic basis for its development. To investigate 
this we undertook a genome-wide association study with the 151 
cases described above and a control cohort of 1748 Crohn’s disease 
and 2361 ulcerative colitis cases.
The strongest association signal for the development of nephro-
toxicity was in the HLA region (rs3135349, odds ratio 2.04, 
p = 1 × 10−7) (see Figure 3 for Manhattan and QQ plots). We there-
fore performed dedicated HLA imputation using SNP2HLA in 
the T1DGC reference panel. The top SNP after imputation was 
rs3135356 (odds ratio 2.0, 95% CI 1.55–3.10, p  =  1 × 10−7). The 
results are shown in Table 2. This association was present in patients 
with Crohn’s disease and ulcerative colitis when tested indepen-
dently (p = 1 × 10−7 and p = 3 × 10−7 respectively).
We recognize that despite the strict adjudication methods under-
taken to assign causality of nephrotoxicity to the administration of 
5-ASA compounds, there might be other factors that we have not 
captured in our data collection that could impact on renal func-
tion. To further refine the phenotype definition we therefore studied 
only those samples classified as definite or probable, who also had 
a renal biopsy demonstrating interstitial nephritis (passed genetic 
QC, n  = 55). Limiting the association analyses to the biopsy-pos-
itive cases significantly strengthened the HLA association signal, 
despite the smaller number of cases, with the most associated SNP 
remaining rs3135356 (Figure 4), but with an odds ratio of 3.1, and 
a genome-wide significant p-value (p = 4 × 10−9). This was robust to 
correction for the first 20 principle components (odds ratio 3.13, 
p = 1 × 10−8). The most associated HLA allele from this analysis was 
HLA-DRB1*03:01 (p = 5 × 10−7, odds ratio 2.76). This variant was 
not associated with duration of therapy prior to the development of 
nephrotoxicity or the likelihood of recovery (p = 0.63 and p = 0.22 
respectively).
Table 1. Montreal classification of disease location and severity in the 2 years prior to development of nephrotoxicity in 151 5-ASA nephro-
toxicity cases.
Ulcerative colitis (n = 93) Crohn’s disease (n = 58)
Extent Severity Location Behaviour
E1 5.5% S0 14.0% L1 5.2% B1 81.1%
E2 20.9% S1 36.6% L2 56.9% B2 17.0%
E3 69.2% S2 45.2% L3 37.9% B3 1.9%
Ex 4.4% S3 4.3% L4 0.0%
Ulcerative colitis (UC) classification:42 E1, ulcerative proctitis; E2, left-sided UC; E3, extensive UC; Ex, unknown. S0, clinical remission; S1, mild UC; S2, moder-
ate UC requiring steroid or immunomodulator; S3, severe UC requiring admission or colectomy.
Crohn’s disease classification:42 L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper. B1, non-stricturing, non-penetrating; B2, stricturing; B3, penetrating.
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4. Discussion
We present here an analysis of the clinical features of patients 
with IBD who developed nephrotoxicity after administration of 
5-ASA compounds. We have conducted the first ever genome-
wide association study of drug-induced renal injury and gone 
on to identify a marker within the HLA region associated with 
5-ASA-induced nephrotoxicity. The data from our cohort suggest 
that 5-ASA-induced nephrotoxicity may present at any age and 
is more common in male patients. The histological hallmark is 
a chronic tubulointerstitial nephritis. Renal injury was detected 
after a median treatment time of 3  years, following which only 
30% of our cohort fully recovered renal function. In 10% of our 
cases, 5-ASA-induced nephrotoxicity necessitated permanent renal 
replacement therapy. These figures must be interpreted carefully, 
however, as the retrospective case identification methods used 
here may have led to recall bias, with greater recruitment of more 
severe cases.
Many drugs have been implicated in the development of inter-
stitial nephritis, but proving causality is difficult. Nephrotoxicity 
induced by 5-ASA has been reported previously in case reports, 
including a case with a positive re-challenge.29 These reports, com-
bined with the 151 cases described here (including the 5 definite 
cases) provide compelling evidence that 5-ASA is able to cause renal 
injury and should be suspected in any patient with deteriorating 
renal function on these agents.
The temporal association between the use of 5-ASA and the 
development of renal injury, the improvement on drug withdrawal 
(although this only occurs in 30% of patients) and the 5 patients 
who were re-challenged with 5-ASA with subsequent worsening of 
renal function provide evidence that the renal damage is likely to 
be drug-related. The relationship between an increased likelihood of 
recovery and drug dose and duration also suggests a pathogenic role 
for the 5-ASA agents in interstitial nephritis development. However, 
there has been a suggestion that the nephrotoxicity observed in IBD 
patients might be an extra-intestinal manifestation of disease rather 
than a result of drug toxicity.12,30 Four of the patients in this study 
had evidence of granulomatous interstitial nephritis with non-case-
ating granulomas seen on biopsy (1 patient with Crohn’s disease, 
2 patients with ulcerative colitis and 1 patient with IBD unclassi-
fied). This rare form of interstitial nephritis is most commonly seen 
in acute drug reactions, but there are isolated case reports of patients 
with IBD developing interstitial nephritis with or without granulo-
mas, some of whom have not been exposed to 5-ASAs.31–33
Current British Society of Gastroenterology guidelines (2011) 
recommend monitoring of renal function annually in patients taking 
5-ASA agents and the European Crohn’s and Colitis Organisation 
(2012) recommends monitoring in high risk patients while the 
American Gastroenterology Society (2010) recommends periodic 
monitoring, noting that evidence for a defined frequency is lack-























Figure 1. Boxplots for the cohort of 151 5-ASA-induced nephrotoxicity cases demonstrating time from treatment commencement with 5-ASA to development 
of nephrotoxicity and subsequent recovery. Serial boxplots demonstrating the median creatinine levels for n = 151 patients taken at each of the 5 study time 
points detailed in the Methods section (note n = 92 for last normal group). The position of the boxplot on the x-axis corresponds to the median time point from 
starting 5-ASA at which these creatinine values were obtained (the width of the boxplot is the 95% confidence interval of this value). The drug was started at time 
point 0 for all patients. The arrow labelled ‘Stop’ illustrates the median time at which the agent was stopped after commencement (the 95% confidence interval 
of this value is indicated by the grey box). Outlier values have not been visualized. Patients who underwent renal replacement therapy were excluded from the 
‘best recovered’ group.
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however, it has been noted that many patients do not have regular 
renal function monitoring whilst using 5-ASA.37 Indeed, data from 
this study suggest that the median time from the last normal creati-
nine to the first abnormal value, which represents how often a patient 
has a blood test, is 1.98 years, with a range of 2 days to 15.3 years.
5-ASA agents are normally tolerated by the majority of patients, 
suggesting an underlying genetic or environmental predisposition to the 
development of renal injury in a small subset of patients. The type of 
renal injury seen with 5-ASA appears to be consistent with the changes 
occasionally seen with long-term lithium use.38 Lithium ingestion over 
a prolonged period of time (usually >2 years) has rarely been associated 
with the development of a chronic focal interstitial cortical fibrosis with 
mononuclear cell infiltrate – a chronic interstitial nephritis.39 Analogous 
to the renal injury seen with 5-ASA, this typically occurs after a pro-
longed period of drug exposure and, once identified by routine blood 










































Figure 2. Time from initiation of 5-ASA agents to the development of nephrotoxicity and recovery of renal function to baseline level. This graph displays the 














































Figure 3. (A) Genome-wide Manhattan plot (including HLA imputation). Blue line, p = 1 × 10−5; red line, p = 5 × 10−8. (B) QQ plot (including HLA imputation).
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We have not attempted to replicate the association of rs3135356 
in an independent population. The collection of cases described 
here required a collection period of 2 years and the involvement of 
89 centres, and consequently further sample collection was felt to 
be unfeasible. An association between another HLA class  II allele, 
HLA-DRB1*01:02, and the rare syndrome of tubulointerstitial 
nephritis and uveitis (TINU) has been described in the literature.41 
The association was only seen in patients with this syndrome and 
not in control patients with interstitial nephritis alone. This associa-
tion is clearly distinct from the drug-induced renal injury displayed 
here and is likely to reflect their separate aetiologies.
Carriage of the risk allele is associated with a 3-fold increased 
risk of renal injury after 5-ASA administration. The high frequency 
of this SNP and the low frequency of the adverse event limits its 
clinical utility and we cannot recommend its use in guiding treat-
ment choice or monitoring intervals.
We describe here an analysis of the clinical features of patients 
with IBD who developed chronic renal damage after administration 
of 5-ASA compounds. We have conducted the first ever association 
study of drug-induced renal injury and identify a genome-wide asso-
ciation with a class II allele. This rare condition appears to be more 
common in male patients, can occur after many years of drug admin-
istration and, once recognized, is only reversible in approximately 
one-third of patients. Although the cost–effectiveness of regular renal 
function measurements has yet to be demonstrated, the potential for 
serious long-term sequelae should necessitate its regular monitoring.
Funding
The International Serious Adverse Events Consortium (iSAEC) funded sam-
ple collection and genotyping. Study feasibility and initiation were supported 
by unrestricted educational grants from Ferring Pharmaceuticals and Warner 
Chilcott UK. Crohn’s and Colitis UK provided funding support and help in 
publicising this study to its members. A Wellcome Trust Institutional Strategic 
Support Award (WT097835MF) generously supported the work in this study. 
RKW is supported by a VIDI grant (016.136.308) from the Netherlands 
Organization for Scientific Research (NWO). We also acknowledge the NIHR 
Biomedical Research Centre awards to Guy’s & St Thomas’ NHS Trust/King’s 
College London and to Addenbrooke’s Hospital/University of Cambridge 
School of Clinical Medicine.
Conflict of Interest
CWL has acted as a consultant to AbbVie, MSD, Takeda, Hospira, 
Pharmacosmos, Vifor Pharma and Dr Falk and received speaking fees and 
travel support from AbbVie, MSD, Takeda, Shire, Ferring, Hospira, Warner-
Chilcott and Dr Falk. CJH has acted on advisory boards or as a consultant 
for Bayer Healthcare, InDex Pharmaceuticals, Novartis Consumer Health and 
Horizon Pharma. JM has done consultancy work for Genentech Inc., Tillotts 
Pharma, NAPP Pharmaceuticals Ltd and Takeda. TC has received honoraria 
and travel support from AbbVie, Ferring, Shire and Warner Chilcott. ML has 
received departmental financial support from Ferring and Warner Chilcott UK, 
speaker honoraria from MSD, travel support from Warner Chilcott UK and 
Vifor Pharma, and was a member of an advisory board for Vifor Pharma. IL 
has received educational grants and speaking endorsements and is a member of 
the advisory board for Shire, Freeing and Colazide. RD’I has received fees for 
Table 2.  Top genome-wide association study (GWAS) association signals from the combined GWAS and HLA imputation analysis.
Single-nucleotide 
polymorphism
Cohort Chromosome Position 
(hg19)




Odds ratio (SE) Odds ratio (95% 
confidence interval)
p-value
rs3135356 All 6 32391516 A 0.17 0.29 2.00 (0.13) 1 × 10−7
Biopsy only 0.39 3.11 (0.19) 4 × 10−9
rs12204929 All 6 119396266 T 0.05 0.11 2.79 (0.20) 4 × 10−7
Biopsy only 0.10 2.26 (0.34) 0.02
rs10488193 All 7 12274220 G 0.11 0.21 2.15 (0.15) 3 × 10−6














































Figure 4. (A) Genome-wide Manhattan plot (including HLA imputation) excluding cases that did not have a renal biopsy demonstrating interstitial nephritis 
(n = 55) for all SNPs with MAF >0.05. Blue line, p = 1 × 10−5; red line, p = 5 × 10−8. (B) QQ plot (including HLA imputation) excluding cases that did not have a renal 
biopsy demonstrating interstitial nephritis (n = 55).
5-ASA-Induced Nephrotoxicity 155
consultancy from AbbVie, MSD and Hospira. RP has received honoraria and 
consultancy fees from and is an advisory board member of Warner Chilcott, 
Dr Falk and Shire, and has received travel assistance from Warner Chilcott, 
Ferring and Dr Falk. PI has received honoraria for acting in an advisory capac-
ity or speaking on behalf of AbbVie, MSD, Takeda, Genentech, Warner Chilcott, 
Ferring, Shire, Tillott’s, Vifor and Pharmacosmos. DW has received honoraria, 
travel and educational grants from Shire, AbbVie, Warner Chilcott and Dr Falk. 
JH has received honoraria for lectures and consultancy from AbbVie, Ferring, 
Hospira, Medivir, MSD, Renapharma Vifor, Swedish Orphan and Takeda. FC 
has received lecture fees and travel support from Ferring Pharmaceuticals, Falk 
and Warner Chilcott. TKD has received lecture fees from Almirall. S. Sebastian 
has received research funding from AbbVie and MSD, honoraria for advi-
sory board membership and speaker fees from Tillots Pharma, Ferring, Falk 
Pharma and AbbVie. MS has received research grants from Janssen, AbbVie 
and Prometheus and consulting and speaker fees from Janssen, AbbVie, Takeda 
and Prometheus. RG has received research support from AbbVie, Pharmatel 
Fresenius Kabi and Ferring, travel support from MSD, AbbVie, Falk and 
Schering-Plough and speaker fees from AbbVie, Janssen and Schering-Plough. 
SW has received speaker fees, sat on advisory boards for MSD and Abbott and 
received travel support from Ferring, MSD and Abbott. TO has received speaker 
fees or travel expenses or is a member of advisory boards for AbbVie, Dr Falk 
Pharma, Ferring UK, Merck, Napp, Warner Chilcott and Vifor Pharma. JB has 
received travel assistance from AbbVie. SCC has received travel assistance from 
AbbVie. RP has received travel assistance from Norgine. MP has received travel 
support and honoraria for lectures from Dr Falk Pharma and Warner Chilcott 
UK. DRG has received travel support and speaker fees from Ferring, Warner 
Chilcott UK, Shire, Tillotts and Dr Falk Pharma. EW has received travel support 
from Dr Falk Pharma. GAH has received travel support from Dr Falk Pharma 
and Tillotts Pharma UK and advisory board payments from AbbVie. TA has 
received unrestricted educational grants from Merck, AbbVie, Ferring, Warner 
Chilcott and speaker and advisory board honoraria from Merck, AbbVie, NAPP, 
Ferring, Warner Chillcott, Falk, Jansen and Takeda. ATC has received unre-
stricted educational support from MSD and Ferring, education/travel support 
from AbbVie, MSD and Dr Falk to attend international meetings and advisory 
board payments from MSD and Ferring. VA has received unrestricted research 
grants from Giuliani, Sofar and Ferring, speaker fees from Ferring, Nycomed and 
Chiesi and travel support from Giuliani, Ferring, Sofar and Chiesi. A. Hart has 
served as consultant, advisory board member or speaker for AbbVie, Atlantic, 
Bristol Meyers Squibb, Celltrion, Falk, Ferring, MSD, Napp Pharmaceuticals, 
Pharmacosmos, Shire and Takeda. AD has received honoraria and uncondi-
tional financial support for educational activities from Warner Chilcott (UK), 
AbbVie, Falk Pharmaceuticals UK, Shire Pharmaceuticals and Takeda. SL has 
received educational support/honoraria from AbbVie, MSD, Warner Chilcott, 
Shire, Ferring and Dr Falk Pharma. C. Murray has acted on advisory boards and 
received speaker fees from AbbVie and MSD. NKdB has participated in an advi-
sory board for Merck, received speaker fees from AbbVie and has received unre-
stricted research grants from Dr Falk Pharma, FM. A. Holden, AS, CB, CJM, 
C. Mowat, DB, EVT, FH, GCS, GRS, KS, LS, MD, M. Thomas, M. Tremelling, 
MW, ND, NE, PD, RC, RD’S, RKW, RO, SG, S. Lewis, SM, S. Sen, TI and TS 
have no conflicts of interest to declare.
Acknowledgments
The International Serious Adverse Events Consortium (iSAEC) funded the 
sample collection and genotyping. Study feasibility and initiation was sup-
ported by unrestricted educational grants from Ferring Pharmaceuticals and 
Warner Chilcott UK. The National Institute for Health Research (NIHR) 
provided research nurse support to facilitate recruitment at all research sites 
located in England. The Swedish Research Council (521-2011-2764) and the 
Örebro University Hospital Research Foundation aided recruitment at Örebro 
University hospital, Sweden. We would like to thank Crohn’s and Colitis UK 
for publicising this study to its members. Genotyping was undertaken at the 
Broad Institute, USA. We would like to thank all the clinicians who assisted 
with sample collection as part of the IBD Pharmacogenetics Study Group 
(listed in the Supplementary Information) and the International IBD Genetics 
Consortium as well as Suzie Marriott for her assistance during trial initia-
tion. We would like to acknowledge The International Serious Adverse Events 
Scientific Management Committee members for their helpful comments. We 
would also like to thank all the patients for their time and participation.
Author Contributions
TA and A. Holden conceived the study. GAH, KS, NE, AS and TA collated 
submitted cases. CB project managed the study. GAH, KS, NE, AS, TA, TKD, 
A. Hart, IL, S. Lewis, CJM, RD’S, RO, TS and EW performed adjudication of 
submitted cases. GAH performed clinical data analysis. GAH and MW per-
formed genetic analysis. VA, JB, DB, RC, ATC, SCC, TC, FC, NKHD, RD’I, 
TKD, MD, AD, ND, PD, DRG, RG, SG, JH, A. Hart, CJH, FH, TI, PI, S. Lal, 
IL, CWL, S. Lal, ML, SM, JM, C. Mowat, FM, C. Murray, TO, MP, R. Phillips, 
R. Pollock, GRS, S. Sebastian, S. Sen, A. Sharma, MS, LS, GCS, M. Thomas, 
M. Tremelling, ET, DW, SW and RKW submitted a substantial number of cases 
and aided drafting of the manuscript. GAH and TA wrote the manuscript, 
which was reviewed by all authors.
Full Author List
Andrew T. Cole, Derby Digestive Diseases Centre, Royal Derby Hospital, Uttoxeter 
Road, Derby, UK; Sheldon C. Cooper, Department of Gastroenterology, Dudley 
Group NHS Foundation Trust, Dudley, UK; Tom Creed, Joint Clinical Research 
Unit, Bristol Royal Infirmary, Bristol UK; Fraser Cummings, Department of 
Gastroenterology, University Hospital Southampton, Southampton, UK; Nanne 
K.  de Boer, Department of Gastroenterology and Hepatology, VU University 
Medical Center, Amsterdam, The Netherlands; Renata D’Inca, Department 
of Surgical, Oncological and Gastroenterological Sciences, University of 
Padua, Padua, Italy; Richard D’Souza, Exeter Kidney Unit, Royal Devon and 
Exeter Foundation Trust, Exeter, UK; Tawfique K. Daneshmend, Department 
of Gastroenterology, Royal Devon and Exeter Foundation Trust, Exeter, UK; 
Michael Delaney, East Kent Hospitals University NHS Foundation Trust, 
Canterbury, UK; Anjan Dhar, Durham University, Durham, UK and County 
Durham & Darlington NHS Foundation Trust, Darlington Memorial Hospital, 
Darlington, UK; Natalie Direkze, Frimley Park Hospital NHS Foundation Trust, 
Frimley, UK; Paul Dunckley, Department of Gastroenterology, Gloucestershire 
Royal Hospital, Gloucester, UK; Daniel R.  Gaya, Gastroenterology Unit, 
Glasgow Royal Infirmary, Glasgow UK; Richard Gearry, Department of 
Gastroenterology, Christchurch Hospital and Department of Medicine, 
University of Otago, Christchurch, New Zealand; Steve Gore, Department of 
Gastroenterology, Yeovil District Hospital, Higher Kingston, Yeovil, UK; Jonas 
Halfvarson, Department of Gastroenterology, Faculty of Medicine and Health, 
Örebro University, Örebro, Sweden; Ailsa Hart, IBD Unit, St Mark’s Hospital, 
Harrow, London and Department of Surgery and Cancer, Imperial College, 
London; Chris J. Hawkey, Nottingham Digestive Diseases Centre, University 
Hospital, Nottingham, UK; Frank Hoentjen, Department of Gastroenterology 
and Hepatology, Radboud University Medical Center, Nijmegen, The 
Netherlands; Tariq Iqbal, Department of Gastroenterology, University 
Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Peter Irving, 
Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust, 
London, UK; Simon Lal, Salford Royal Foundation Trust, Salford, UK and 
University of Manchester, Manchester, UK; Ian Lawrence, School of Medicine 
and Pharmacology, University of Western Australia, Harry Perkins Institute for 
Medical Research,UWA, Murdoch, WA, Australia and Centre for inflammatory 
Bowel Diseases, Saint John of God Hospital, Subiaco, WA, Australia; Charlie 
W.  Lees, Gastrointestinal Unit, Western General Hospital, Edinburgh, UK; 
Steve Lewis, Department of Gastroenterology, Derriford Hospital, Plymouth, 
Devon, UK; Melanie Lockett, North Bristol NHS Trust, Southmead Hospital, 
Bristol, UK; Stephen Mann, Department of Gastroenterology, Barnet Hospital, 
Barnet, UK; John Mansfield, Royal Victoria Infirmary, Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle, UK and Institute of Genetic 
Medicine, Newcastle University, Newcastle, UK; Craig Mowat, Department of 
Gastroenterology, Ninewells Hospital and Medical School, Dundee, UK; Chris 
J Mulgrew, Exeter Kidney Unit, Royal Devon and Exeter Foundation Trust, 
Exeter, UK; Frank Muller, The Kent & Canterbury Hospital, Canterbury, UK; 
Charles Murray, Department of Gastroenterology, Royal Free Hospital, London, 
UK; Richard Oram, Exeter Kidney Unit, Royal Devon and Exeter Foundation 
Trust, Exeter, UK and Precision Medicine Exeter, University of Exeter, Exeter, 
156 G. A. Heap et al.
UK; Tim Orchard, Imperial College Healthcare NHS Trust, St Mary’s Hospital, 
London, UK; Miles Parkes, Division of Gastroenterology, Department of 
Medicine, Addenbrooke’s Hospital, Cambridge, UK; Rosemary Phillips, 
Department of Gastroenterology, Princess Alexandra Hospital NHS Trust, 
Harlow, UK; Richard Pollok, Department of Gastroenterology, St George’s 
NHS Trust and St George’s University of London, London, UK; Graham 
Radford-Smith, Inflammatory Bowel Disease Research Group, Queensland 
Institute of Medical Research, Brisbane, Australia; Shaji Sebastian, Hull & East 
Yorkshire NHS Trust, Hull, UK; Sandip Sen, Department of Gastroenterology, 
University Hospitals of North Midlands NHS Trust, Royal Stoke University 
Hospital, Stoke-on-Trent, UK; Tarek Shirazi, Department of Gastroenterology, 
Royal Devon and Exeter Foundation Trust, Exeter, UK; Mark Silverberg, 
Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Division of 
Gastroenterology, University of Toronto, Toronto, Canada; Laurie Solomon, 
Lancashire Teaching Hospitals, Royal Preston Hospital, Preston, UK; Giacomo 
C.  Sturniolo, Department of Surgical, Oncological and Gastroenterological 
Sciences, University of Padua, Padua, Italy; Mark Thomas, Department of Renal 
Medicine, Birmingham Heartlands Hospital, Heart of England Foundation 
Trust, Birmingham, UK; Mark Tremelling, Norfolk and Norwich University 
Hospital, Norwich, UK; Epameinondas V.  Tsianos, 1st Division of Internal 
Medicine and Division of Gastroenterology, Faculty of Medicine, University 
of Ioannina, Ioannina, Greece; David Watts, Gastrointestinal Unit, NHS Forth 
Valley, Forth Valley Royal Hospital, Larbert, UK; Sean Weaver, Department 
of Gastroenterology, Royal Bournemouth Hospital, Bournemouth, UK; Rinse 
K.  Weersma, Department of Gastroenterology and Hepatology, University 
of Groningen and University Medical Center Groningen, Groningen, The 
Netherlands; Emma Wesley, Department of Gastroenterology, Musgrove Park 
NHS Hospital, Taunton, UK; Arthur Holden, The International Serious Adverse 
Events Consortium, Chicago, IL, USA; Tariq Ahmad, IBD Pharmacogenetics, 
Royal Devon and Exeter Foundation Trust, Exeter, UK and Precision Medicine 
Exeter, University of Exeter, Exeter, UK
References
 1. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for mainte-
nance of remission in ulcerative colitis. Cochrane Database Syst Rev 
2012;10:CD000544.
 2. Sandborn WJN, Hanauer SB. Systematic review: the pharmacokinetic pro-
files of oral mesalazine formulations and mesalazine pro-drugs used in the 
management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29–42.
 3. Chester AC, Diamond LH, Schreiner GE. Hypersensitivity to salicy-
lazosulfapyridine: renal and hepatic toxic reactions. Arch Intern Med 
1978;138:1138–9.
 4. Calviño J, Romero R, Pintos E, et al. Mesalazine-associated tubulo-intersti-
tial nephritis in inflammatory bowel disease. Clin Nephrol 1998;49:265–7.
 5. Dwarakanath AD, Michael J, Allan RN. Sulphasalazine induced renal fail-
ure. Gut 1992;33:1006–7.
 6. Alivanis P, Aperis G, Lambrianou F, et al. Reversal of refractory sulfasala-
zine-related renal failure after treatment with corticosteroids. Clin Ther 
2010;32:1906–10.
 7. Popoola J, Muller AF, Pollock L, O’Donnell P, Carmichael P, Stevens P. 
Late onset interstitial nephritis associated with mesalazine treatment. BMJ 
1998;317:795–7.
 8. Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report 
and literature review. Pediatr Nephrol 2004;19:550–3.
 9. UK Committee on Safety of Medicines. Current Problems No. 30: Nephro-
toxicity associated with mesalazine (Asacol). 1990.
 10. Muller AF, Stevens PE, McIntyre AS, Ellison H, Logan RF. Experience of 
5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Phar-
macol Ther 2005;21:1217–24.
 11. Gisbert JP, Luna M, González-Lama Y, et al. Effect of 5-aminosalicylates 
on renal function in patients with inflammatory bowel disease: 4-year 
follow-up study. Gastroenterol Hepatol 2008;31:477–84.
 12. Van Staa TP, Travis S, Leufkens HGM, Logan RF. 5-Aminosalicylic acids 
and the risk of renal disease: a large British epidemiologic study. Gastro-
enterology 2004;126:1733–9.
 13. Contreras JL, Floratos A, Holden AL. The International Serious 
Adverse Events Consortium’s data sharing model. Nat Biotechnol 
2013;31:17–9.
 14. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a 
major determinant of drug-induced liver injury due to flucloxacillin. Nat 
Genet 2009;41:816–9.
 15. Heap GA, Weedon MN, Bewshea CM, et  al. HLA-DQA1-HLA-DRB1 
variants confer susceptibility to pancreatitis induced by thiopurine immu-
nosuppressants. Nat Genet 2014;46:1131–4.
 16. Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater 
reliability of the Liverpool adverse drug reaction causality assessment tool. 
PLoS One 2011;6:e28096.
 17. R Core Team. R: A language and environment for statistical computing. 
http://www.r-project.org.
 18. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: 
enabling an accurate, cost-effective approach to high-throughput genotyp-
ing. Biotechniques 2002;Suppl:56–8, 60–1.
 19. Goldstein JI, Crenshaw A, Carey J, et al. zCall: a rare variant caller for 
array-based genotyping: genetics and population analysis. Bioinformatics 
2012;28:2543–5.
 20. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines 
more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 
2008;40:955–62.
 21. Anderson CA, Boucher G, Lees CW, et  al. Meta-analysis identifies 29 
additional ulcerative colitis risk loci, increasing the number of confirmed 
associations to 47. Nat Genet 2011;43:246–52.
 22. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-
wide complex trait analysis. Am J Hum Genet 2011;88:76–82.
 23. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. 
Robust relationship inference in genome-wide association studies. Bioin-
formatics 2010;26:2867–73.
 24. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and 
accurate genotype imputation in genome-wide association studies through 
pre-phasing. Nat Genet 2012;955–9.
 25. Jia X, Han B, Onengut-Gumuscu S, et al. Imputing amino acid polymor-
phisms in human leukocyte antigens. PLoS One 2013;8:e64683.
 26. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and 
genotype data to estimate haplotypes and unobserved genotypes. Genet 
Epidemiol 2010;34:816–34.
 27. Purcell S, Neale B, Todd-Brown K, et  al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum 
Genet 2007;81:559–75. 
 28. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated 
interstitial nephritis. Nephrol Dial Transplant 1996;11:614–21.
 29. Manenti L, De Rosa A, Buzio C. Mesalazine-associated intersti-
tial nephritis: twice in the same patient. Nephrol Dial Transplant 
1997;12:2031.
 30. Waters AM, Zachos M, Herzenberg AM, Harvey E, Rosenblum ND. 
Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn’s 
disease. Nat Clin Pract Nephrol 2008;4:693–7.
 31. Bijol V, Mendez GP, Nose V, Rennke HG. Granulomatous interstitial 
nephritis: a clinicopathologic study of 46 cases from a single institution. 
Int J Surg Pathol 2006;14:57–63.
 32. Izzedine H, Simon J, Piette A, et al. Primary chronic interstitial nephritis in 
Crohn’s disease. Gastroenterology 2002;123:1436–40.
 33. Colvin RB, Traum AZ, Taheri D, Jafari M, Dolatkhah S. Granulomatous 
interstitial nephritis as a manifestation of Crohn disease. Arch Pathol Lab 
Med 2014;138:125–7.
 34. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: 
American College of Gastroenterology, Practice Parameters Committee. 
Am J Gastroenterol 2010;105:501–23; quiz 524.
 35. Dignass A, Van Assche G, Lindsay JO, et  al. The second European evi-
dence-based Consensus on the diagnosis and management of Crohn’s dis-
ease: current management. J Crohns Colitis 2010;4:28–62.
 36. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of 
inflammatory bowel disease in adults. Gut 2011;60:571–607.
5-ASA-Induced Nephrotoxicity 157
 37. Siddique N, Farmer C, Muller AF. Do gastroenterologists monitor their 
patients taking 5-amino-salicylates following initiation of treatment. 
Frontline Gastroenterol 2014. Doi: 10.1136/flgastro-2014-100452.
 38. Hestbech J, Hansen HE, Amdisen A, Olsen S. Chronic renal lesions 
following long-term treatment with lithium. Kidney Int 1977;12:205–
13.
 39. Hansen HE, Hestbech J, Sørensen JL, Nørgaard K, Heilskov J, Amdisen 
A. Chronic interstitial nephropathy in patients on long-term lithium treat-
ment. Q J Med 1979;48:577–91.
 40. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, 
D’Agati VD. Lithium nephrotoxicity: a progressive combined glomerular 
and tubulointerstitial nephropathy. J Am Soc Nephrol 2000;11:1439–48.
 41. Mackensen F, David F, Schwenger V, et al. HLA-DRB1*0102 is associated 
with TINU syndrome and bilateral, sudden-onset anterior uveitis but not 
with interstitial nephritis alone. Br J Ophthalmol 2011;95:971–5.
 42. Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal clas-
sification of inflammatory bowel disease: controversies, consensus, and 
implications. Gut 2006;55:749–53.
158 G. A. Heap et al.
